Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Asset Turnover : 0.10 (As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Clarus Therapeutics Holdings Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Clarus Therapeutics Holdings's Revenue for the three months ended in Jun. 2022 was $4.05 Mil. Clarus Therapeutics Holdings's Total Assets for the quarter that ended in Jun. 2022 was $42.73 Mil. Therefore, Clarus Therapeutics Holdings's Asset Turnover for the quarter that ended in Jun. 2022 was 0.10.

Asset Turnover is linked to ROE % through Du Pont Formula. Clarus Therapeutics Holdings's annualized ROE % for the quarter that ended in Jun. 2022 was 197.03%. It is also linked to ROA % through Du Pont Formula. Clarus Therapeutics Holdings's annualized ROA % for the quarter that ended in Jun. 2022 was -100.11%.

Clarus Therapeutics Holdings Asset Turnover Historical Data

The historical data trend for Clarus Therapeutics Holdings's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarus Therapeutics Holdings Asset Turnover Chart

Clarus Therapeutics Holdings Annual Data

Trend

Dec20

Dec21

Asset Turnover

0.33

0.39

Clarus Therapeutics Holdings Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Asset Turnover	Get a 7-Day Free Trial			-	0.10	0.09	0.09	0.10

Competitive Comparison of Clarus Therapeutics Holdings's Asset Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, Clarus Therapeutics Holdings's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clarus Therapeutics Holdings's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Clarus Therapeutics Holdings's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Clarus Therapeutics Holdings's Asset Turnover falls into.

Clarus Therapeutics Holdings Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Clarus Therapeutics Holdings's Asset Turnover for the fiscal year that ended in Dec. 2021 is calculated as

	Asset Turnover
=	Revenue	/	Average Total Assets
=	Revenue (A: Dec. 2021 )	/	( (Total Assets (A: Dec. 2020 )	+	Total Assets (A: Dec. 2021 ))	/ count )
=	13.957	/	( (19.4	+	51.708)	/ 2 )
=	13.957	/	35.554
=	0.39

Clarus Therapeutics Holdings's Asset Turnover for the quarter that ended in Jun. 2022 is calculated as

	Asset Turnover
=	Revenue	/	Average Total Assets
=	Revenue (Q: Jun. 2022 )	/	( (Total Assets (Q: Mar. 2022 )	+	Total Assets (Q: Jun. 2022 ))	/ count )
=	4.05	/	( (36.522	+	48.94)	/ 2 )
=	4.05	/	42.731
=	0.09

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Clarus Therapeutics Holdings (OTCPK:CRXTQ) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Clarus Therapeutics Holdings's annulized ROE % for the quarter that ended in Jun. 2022 is

	ROE %^**		(Q: Jun. 2022 )
=	Net Income	/	Total Stockholders Equity
=	-42.776	/	-21.71
=	(Net Income / Revenue)	*	(Revenue / Total Assets)	*	(Total Assets / Total Stockholders Equity)
=	(-42.776 / 16.2)	*	(16.2 / 42.731)	*	(42.731/ -21.71)
=	Net Margin %	*	Asset Turnover	*	Equity Multiplier
=	-264.05 %	*	0.3791	*	-1.9683
=	ROA %	*	Equity Multiplier
=	-100.11 %	*	-1.9683
=	197.03 %

Note: The Net Income data used here is four times the quarterly (Jun. 2022) net income data. The Revenue data used here is four times the quarterly (Jun. 2022) revenue data.

^** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Clarus Therapeutics Holdings's annulized ROA % for the quarter that ended in Jun. 2022 is

	ROA %		(Q: Jun. 2022 )
=	Net Income	/	Total Assets
=	-42.776	/	42.731
=	(Net Income / Revenue)	*	(Revenue / Total Assets)
=	(-42.776 / 16.2)	*	(16.2 / 42.731)
=	Net Margin %	*	Asset Turnover
=	-264.05 %	*	0.3791
=	-100.11 %

Note: The Net Income data used here is four times the quarterly (Jun. 2022) net income data. The Revenue data used here is four times the quarterly (Jun. 2022) revenue data.

Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.

Clarus Therapeutics Holdings Asset Turnover Related Terms

Thank you for viewing the detailed overview of Clarus Therapeutics Holdings's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Clarus Therapeutics Holdings Inc (OTCPK:CRXTQ) » Definitions » Asset Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

555 Skokie Boulevard, Suite 340, Northbrook, IL, USA, 60062

Website

https://www.clarustherapeutics.com

Clarus Therapeutics Holdings Inc is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is focused on focused on the commercialization of JATENZO (testosterone undecanoate), the first and only oral testosterone replacement, or testosterone replacement therapy, and JATENZO is the sole source of company's revenue.

Executives

Thomas Mcnerney & Partners Lp	10 percent owner	45 S. 7TH ST., SUITE 3060, MINNEAPOLIS MN 55402
Kimberly M Murphy	director	101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Elizabeth Cermak	director	1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Prygocki Mark A Sr	director	C/O MEDICS, 8125 N. HAYDEN RD, SCOTTSDALE AZ 85258
John Kenneth Amory	director	C/O CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Robert E. Dudley	director, officer: Chief Executive Officer	555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Joseph Hernandez	director	C/O MICROLIN BIO, INC., NEW YORK NY 10022
Richard D Peterson	officer: Chief Financial Officer	1110 WEST COMMERCIAL BOULEVARD, FORT LAUDERDALE FL 33309
Frank Jaeger	officer: Chief Commercial Officer	CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Steven A. Bourne	officer: Chief Administrative Officer	555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Ffi Fund Ltd	10 percent owner	DMS HOUSE, 20 GENESIS CLOSE, GRAND CAYMAN, GEORGE TOWN E9 KY1-1208
Thomas, Mcnerney & Partners Ii L.p.	10 percent owner	45 SOUTH 7TH STREET, SUITE 3060, Minneapolis MN 55402
Thomas, Mcnerney & Partners Ii, Llc	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Nominee Ii, Llc	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Associates Ii Lp	10 percent owner	45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402